BR9405856A - Processo para redução de viscosidade de conteúdo de vias aéreas mocóides patológicos no trato respiratório - Google Patents
Processo para redução de viscosidade de conteúdo de vias aéreas mocóides patológicos no trato respiratórioInfo
- Publication number
- BR9405856A BR9405856A BR9405856A BR9405856A BR9405856A BR 9405856 A BR9405856 A BR 9405856A BR 9405856 A BR9405856 A BR 9405856A BR 9405856 A BR9405856 A BR 9405856A BR 9405856 A BR9405856 A BR 9405856A
- Authority
- BR
- Brazil
- Prior art keywords
- contents
- actin
- pathological
- respiratory tract
- viscosity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4716—Muscle proteins, e.g. myosin, actin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/53—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/042,247 US5464817A (en) | 1990-04-11 | 1993-04-02 | Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I |
PCT/US1994/003667 WO1994022465A1 (en) | 1993-04-02 | 1994-04-04 | Method for reducing the viscosity of pathological mucoid airway contents in the respiratoy tract |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9405856A true BR9405856A (pt) | 1996-03-05 |
Family
ID=21920852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9405856A BR9405856A (pt) | 1993-04-02 | 1994-04-04 | Processo para redução de viscosidade de conteúdo de vias aéreas mocóides patológicos no trato respiratório |
Country Status (17)
Country | Link |
---|---|
US (2) | US5464817A (pt) |
EP (1) | EP0692970B1 (pt) |
JP (2) | JPH08510998A (pt) |
KR (1) | KR100308679B1 (pt) |
CN (1) | CN1107521C (pt) |
AT (1) | ATE182790T1 (pt) |
AU (1) | AU695033B2 (pt) |
BR (1) | BR9405856A (pt) |
CA (1) | CA2159205A1 (pt) |
DE (1) | DE69419907T2 (pt) |
DK (1) | DK0692970T3 (pt) |
ES (1) | ES2135576T3 (pt) |
GB (1) | GB2293102B (pt) |
GR (1) | GR3031753T3 (pt) |
NO (1) | NO953862D0 (pt) |
SG (1) | SG49574A1 (pt) |
WO (1) | WO1994022465A1 (pt) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5464817A (en) * | 1990-04-11 | 1995-11-07 | Brigham And Women's Hospital | Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I |
US5691160A (en) * | 1992-08-14 | 1997-11-25 | Biogen, Inc. | Effects of actin filaments of fibrin clot structure and lysis |
US5593964A (en) * | 1993-10-07 | 1997-01-14 | The George Washington University Medical Center | Method of treating septic shock by preventing actin polymerization |
US5578570A (en) * | 1993-10-07 | 1996-11-26 | The George Washington University Medical Center | Method of treating septic shock using thymosin β4 |
PT811068E (pt) * | 1995-02-24 | 2003-04-30 | Genentech Inc | Variantes da adnase i humana |
US6348343B2 (en) | 1995-02-24 | 2002-02-19 | Genentech, Inc. | Human DNase I variants |
SK284191B6 (sk) | 1995-02-24 | 2004-10-05 | Genentech, Inc. | Aktín-rezistentný variant humánnej DNázy I |
PT854927E (pt) * | 1995-10-10 | 2008-09-08 | Genentech Inc | Variantes da adnase i humana |
US6391607B1 (en) | 1996-06-14 | 2002-05-21 | Genentech, Inc. | Human DNase I hyperactive variants |
WO1998024465A1 (en) | 1996-12-04 | 1998-06-11 | The Victoria University Of Manchester | Wound healing and treatment of fibrosis |
EP1249244A1 (en) * | 2001-04-13 | 2002-10-16 | Universiteit Gent | Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease |
CN1329078C (zh) * | 2001-12-28 | 2007-08-01 | 阿斯比奥制药株式会社 | 造血干细胞和/或造血前体细胞的增殖和/或分化促进剂 |
US8388951B2 (en) | 2003-07-14 | 2013-03-05 | Cls Therapeutics Limited | Method for treating systemic DNA mutation disease |
US8431123B2 (en) * | 2003-07-14 | 2013-04-30 | Cls Therapeutics Limited | Method for treating systemic bacterial, fungal and protozoan infection |
US8710012B2 (en) | 2003-07-14 | 2014-04-29 | Cls Therapeutics Limited | Method for treating oncological diseases |
WO2005004904A1 (fr) * | 2003-07-14 | 2005-01-20 | Dmitry Dmitrievich Genkin | Methode de traitement de maladies s'accompagnant d'alterations de la composition qualitative et/ou quantitative de l'adn extracellulaire du sang (variantes) |
GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
WO2005046454A2 (en) * | 2003-11-12 | 2005-05-26 | Trustrees Of The University Of Pennsylvania | Methods of using gelsolin to treat or prevent bacterial sepsis |
US9408891B2 (en) * | 2003-11-12 | 2016-08-09 | The Trustees Of The University Of Pennsylvania | Methods of using gelsolin to treat or prevent bacterial sepsis |
US8518457B2 (en) * | 2004-05-11 | 2013-08-27 | Pulmonox Technologies Corporation | Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant |
WO2005112970A2 (en) * | 2004-05-12 | 2005-12-01 | The Brigham And Women's Hospital, Inc. | Use of gelsolin to treat infections |
US20060030539A1 (en) * | 2004-08-06 | 2006-02-09 | National Jewish Medical And Research Center | Product and process for inhibition of biofilm development |
EP1880733A4 (en) * | 2005-04-25 | 2009-08-12 | Genkin Dmitry Dmitrievich | METHOD FOR EXTENDING THE LIFE OF A HUMAN AND ANIMALS |
PL2001496T3 (pl) | 2006-03-15 | 2017-10-31 | Brigham & Womens Hospital Inc | Zastosowanie gelsoliny do diagnozowania i leczenia chorób zapalnych |
CN101460843B (zh) * | 2006-03-15 | 2018-06-22 | 布赖汉姆妇女医院有限公司 | 凝溶胶蛋白治疗多发性硬化和诊断神经疾病的用途 |
PL2095825T3 (pl) * | 2006-11-28 | 2011-12-30 | Cls Therapeutics Ltd | Sposób leczenia ludzkich chorób związanych ze zwiększoną zawartością kwasu deoksyrybonukleinowego w przestrzeniach pozakomórkowych i tkankach i preparat leczniczy do przeprowadzenia tego sposobu |
WO2008101084A2 (en) | 2007-02-15 | 2008-08-21 | National Jewish Medical And Research Center | Methods and compositions for the disruption of biofilms |
CA3080273C (en) * | 2008-01-25 | 2022-11-22 | The General Hospital Corporation | Diagnostic and therapeutic uses of gelsolin in renal failure |
WO2013114371A1 (en) | 2012-02-01 | 2013-08-08 | Protalix Ltd. | Dry powder formulations of dnase i |
US10617743B2 (en) | 2014-06-19 | 2020-04-14 | Cls Therapeutics Limited | Method to improve safety and efficacy of anti-cancer therapy |
ES2799515T3 (es) | 2015-05-22 | 2020-12-18 | Dmitry Dmitrievich Genkin | ADN extracelular como una diana terapéutica en la neurodegeneración |
KR20200122320A (ko) | 2018-01-16 | 2020-10-27 | 씨엘에스 테라퓨틱스 리미티드 | 데옥시리보뉴클레아제 (dnase) 활성을 갖는 효소의 간 발현에 의한 질환의 치료 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5464817A (en) * | 1990-04-11 | 1995-11-07 | Brigham And Women's Hospital | Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I |
WO1991015770A1 (en) * | 1990-04-11 | 1991-10-17 | The General Hospital Corporation | Therapeutic uses of actin-binding compounds |
US5691160A (en) * | 1992-08-14 | 1997-11-25 | Biogen, Inc. | Effects of actin filaments of fibrin clot structure and lysis |
-
1993
- 1993-04-02 US US08/042,247 patent/US5464817A/en not_active Expired - Lifetime
-
1994
- 1994-04-04 DE DE69419907T patent/DE69419907T2/de not_active Expired - Fee Related
- 1994-04-04 SG SG1995001962A patent/SG49574A1/en unknown
- 1994-04-04 WO PCT/US1994/003667 patent/WO1994022465A1/en active IP Right Grant
- 1994-04-04 JP JP6522448A patent/JPH08510998A/ja active Pending
- 1994-04-04 DK DK94914023T patent/DK0692970T3/da active
- 1994-04-04 ES ES94914023T patent/ES2135576T3/es not_active Expired - Lifetime
- 1994-04-04 CN CN94191951A patent/CN1107521C/zh not_active Expired - Fee Related
- 1994-04-04 AU AU66250/94A patent/AU695033B2/en not_active Ceased
- 1994-04-04 EP EP94914023A patent/EP0692970B1/en not_active Expired - Lifetime
- 1994-04-04 GB GB9520020A patent/GB2293102B/en not_active Expired - Fee Related
- 1994-04-04 CA CA002159205A patent/CA2159205A1/en not_active Abandoned
- 1994-04-04 BR BR9405856A patent/BR9405856A/pt not_active Application Discontinuation
- 1994-04-04 KR KR1019950704203A patent/KR100308679B1/ko not_active IP Right Cessation
- 1994-04-04 AT AT94914023T patent/ATE182790T1/de not_active IP Right Cessation
-
1995
- 1995-06-02 US US08/458,351 patent/US5656589A/en not_active Expired - Fee Related
- 1995-09-29 NO NO953862A patent/NO953862D0/no not_active Application Discontinuation
-
1999
- 1999-11-04 GR GR990402778T patent/GR3031753T3/el unknown
-
2001
- 2001-04-03 JP JP2001105286A patent/JP2001302537A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0692970A1 (en) | 1996-01-24 |
GB2293102B (en) | 1996-10-09 |
GB2293102A (en) | 1996-03-20 |
GR3031753T3 (en) | 2000-02-29 |
ES2135576T3 (es) | 1999-11-01 |
SG49574A1 (en) | 1998-06-15 |
JP2001302537A (ja) | 2001-10-31 |
ATE182790T1 (de) | 1999-08-15 |
KR100308679B1 (ko) | 2001-11-30 |
JPH08510998A (ja) | 1996-11-19 |
AU695033B2 (en) | 1998-08-06 |
NO953862L (no) | 1995-09-29 |
WO1994022465A1 (en) | 1994-10-13 |
DE69419907T2 (de) | 1999-12-09 |
AU6625094A (en) | 1994-10-24 |
CA2159205A1 (en) | 1994-10-13 |
CN1122108A (zh) | 1996-05-08 |
DK0692970T3 (da) | 1999-12-06 |
CN1107521C (zh) | 2003-05-07 |
US5464817A (en) | 1995-11-07 |
DE69419907D1 (de) | 1999-09-09 |
NO953862D0 (no) | 1995-09-29 |
EP0692970B1 (en) | 1999-08-04 |
GB9520020D0 (en) | 1995-12-06 |
US5656589A (en) | 1997-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9405856A (pt) | Processo para redução de viscosidade de conteúdo de vias aéreas mocóides patológicos no trato respiratório | |
BR9608449A (pt) | Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica. | |
DK1094834T3 (da) | Farmaceutisk sammensætning til behandling af funktionel dybspepsi og/eller irritabel tarmsyndrom samt ny anvendelse deraf | |
BR9713521A (pt) | ||
BR9607601A (pt) | Uso de ácido hialurÈnico para o tratamento de cistite intersticial | |
CY1112330T1 (el) | Πρωτεϊνες συνδεσης gag | |
DE69130289D1 (de) | Therapeutische verwendung von actin-bindenden verbindungen | |
WO2003055979A3 (en) | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS | |
DE60025008D1 (de) | Bestimmung von adrenomedullin-bindenden proteinen | |
BR9914631A (pt) | Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades | |
FI943028A (fi) | Happoa kestävä FGF-koostumus ja menetelmä ruoansulatuskanavassa esiintyvien, haavaumia aiheuttavien sairauksien hoitamiseksi | |
ATE338130T1 (de) | Cdna für humane methyllentetrahydrofolatreduktase | |
DE69516416D1 (de) | Feststellung der wechselwirkungsstelle zwischen p21-waf und pcna und deren therapeutischen verwendungen | |
NO885013D0 (no) | Fremgangsmte for fremstilling av bionedbrytbare mikrokapsler av vannopplelige peptider og proteiner, samt mikroka psler oppndd ved fremgangsmten. | |
WO2004020668A3 (en) | Method for treating synovial sarcoma | |
DE60036555D1 (de) | Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter | |
BR9808729A (pt) | Processo para a preparação de um anti-oxidante | |
PT782630E (pt) | Gene da doenca poliquistica do rim | |
IL129910A0 (en) | Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis | |
NZ334762A (en) | Human DNase I variants having binding affinity to actin | |
BR9909180A (pt) | Utilização de pelo menos um fragmento de uma proteìna de membrana e processo de prepração de uma proteìna ou um de seus fragmentos por via recombinante | |
BR9510323A (pt) | Variante de dnase i humana ácido nucleico isolado método para tratamento de um paciente tendo uma desordem ou doença pulmonar e composição farmacêutica | |
ES2063161T3 (es) | Proteinas modificadas. | |
KR950003312A (ko) | 연골세포 단백질 | |
TR200002611T2 (tr) | Beta-lipotropin ve kullanımları |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
B15K | Others concerning applications: alteration of classification |
Ipc: C07K 14/47 (2006.01), A61K 38/17 (2006.0 |